Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

A new review was published in , Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." ...

Innovations in therapeutic strategies, coupled with a deeper understanding of breast cancer biology, will be essential for advancing personalized ...

Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according ...

The presence of biomarkers, even in small amounts, can shape the course of treatment for a patient, says Andy Guinigundo, MSN, RN, CNP, ANP-BC.

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth ...

Leiden, the Netherlands Saturday, March 22, 2025, 12:00 Hrs [IST] ...

Type 2 diabetes mellitus (T2DM) is a prevalent yet complex metabolic disorder that has shown a rising incidence over the past few decades. Recent research has identified flavonoids as compounds ...

Direct-acting antivirals (DAAs) have dramatically changed the landscape of chronic hepatitis C virus (HCV) treatment and ...

Particularly noteworthy among these compounds are 6-gingerol and 6-shogaol, which have been recognized for their potent ...

Hepatitis C virus (HCV) infection remains a major global health burden, affecting millions worldwide and contributing significantly to hepatocellular carcinoma (HCC) development.